Skip NavigationSkip to Content

How to Achieve Better Results Using PASS-Based Virtual Screening: Case Study for Kinase Inhibitors

  1. Author:
    Pogodin, Pavel V
    Lagunin, Alexey A
    Rudik, Anastasia V
    Filimonov, Dmitry A
    Druzhilovskiy, Dmitry S
    Nicklaus, Marc
    Poroikov, Vladimir V
  2. Author Address

    Department of Bioinformatics, Institute of Biomedical Chemistry, Moscow, Russia., Department of Bioinformatics, Medical-Biological Department, Pirogov Russian National Research Medical University, Moscow, Russia., Computer-Aided Drug Design Group, Chemical Biology Laboratory, Center for Cancer Research, National Cancer Institute, NIH, NCI-Frederick, Frederick, MD, United States.,
    1. Year: 2018
    2. Date: Apr 26
    3. Epub Date: 2018 04 26
  1. Journal: Frontiers in chemistry
    1. 6
    2. Pages: 133
  2. Type of Article: Article
  3. Article Number: 133
  4. ISSN: 2296-2646
  1. Abstract:

    Discovery of new pharmaceutical substances is currently boosted by the possibility of utilization of the Synthetically Accessible Virtual Inventory (SAVI) library, which includes about 283 million molecules, each annotated with a proposed synthetic one-step route from commercially available starting materials. The SAVI database is well-suited for ligand-based methods of virtual screening to select molecules for experimental testing. In this study, we compare the performance of three approaches for the analysis of structure-activity relationships that differ in their criteria for selecting of "active" and "inactive" compounds included in the training sets. PASS (Prediction of Activity Spectra for Substances), which is based on a modified Na 239;ve Bayes algorithm, was applied since it had been shown to be robust and to provide good predictions of many biological activities based on just the structural formula of a compound even if the information in the training set is incomplete. We used different subsets of kinase inhibitors for this case study because many data are currently available on this important class of drug-like molecules. Based on the subsets of kinase inhibitors extracted from the ChEMBL 20 database we performed the PASS training, and then applied the model to ChEMBL 23 compounds not yet present in ChEMBL 20 to identify novel kinase inhibitors. As one may expect, the best prediction accuracy was obtained if only the experimentally confirmed active and inactive compounds for distinct kinases in the training procedure were used. However, for some kinases, reasonable results were obtained even if we used merged training sets, in which we designated as inactives the compounds not tested against the particular kinase. Thus, depending on the availability of data for a particular biological activity, one may choose the first or the second approach for creating ligand-based computational tools to achieve the best possible results in virtual screening.

    See More

External Sources

  1. DOI: 10.3389/fchem.2018.00133
  2. PMID: 29755970
  3. PMCID: PMC5935003
  4. WOS: 000430933500001

Library Notes

  1. Fiscal Year: FY2017-2018
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel